r The short-chain fatty acids (SCFAs) are bacterial metabolites produced during the colonic fermentation of undigested carbohydrates, such as dietary fibre and prebiotics, and can mediate the interaction between the diet, the microbiota and the host.
Introduction
The short-chain fatty acids (SFCAs), mainly comprising acetate, propionate and butyrate, are produced in the large intestine by microbial degradation of undigested carbohydrates and, to a lesser extent, proteins. They are increasingly recognized as signalling molecules that mediate the interaction between the diet, the gut microbiota and the host. Locally in the gut, SCFAs are crucial for intestinal health because they serve as the major energy substrates for the colonocytes and also because of their anti-inflammatory and anti-carcinogenic properties (Hamer et al. 2008) . In addition, they affect gut and host metabolism by activating the G-protein coupled cell surface receptors GPR-41 and GPR-43 (Brown et al. 2003) , later renamed as free fatty acid receptors (FFAR)-3 and FFAR-2, which are involved in the regulation of glucose and lipid metabolism (den Besten et al. 2013b) . Activation of those receptors on the enteroendocrine L-cells in the colon results in the secretion of the gut-derived satiety hormones glucagon-like peptide 1 and peptide YY, providing a mechanism for the beneficial effect of SCFAs on energy intake and satiety (Canfora et al. 2015) . Finally, a fraction of the colonic produced SCFAs reaches the systemic circulation and directly affects the function and metabolism of peripheral organs and tissues, such as the liver, the pancreas, adipocytes, immune cells and skeletal muscle tissue. As a consequence, SCFAs have been involved in maintaining glucose and lipid metabolism and may provide an important target for tackling disorders that are associated with disturbances of glucose and lipid metabolism, such as obesity, metabolic syndrome or type 2 diabetes.
To further understand how SCFAs provide a mechanistic link between the diet, the microbiota and health benefits, it is necessary to quantify the extent to which fermentation-derived SCFAs reach the systemic circulation. Quantitative information on the assimilation of SCFAs into biologically relevant molecules in humans may also contribute to unravelling the mechanism by which SCFAs elicit systemic effects. Currently, SCFAs are most often measured in faeces or in fasting blood samples. However, because of the rapid absorption of SCFAs by the colonocytes, only an estimated 5% of produced SCFAs is excreted in faeces (McNeil et al. 1978) , rendering faecal measurements unrepresentative of colonic SCFA production. In addition, extensive metabolism in colonocytes and the liver results in low plasma levels of SCFAs.
In the present study, stable isotope technology was applied to determine the systemic availability of each SCFA after colonic administration of 13 C-labelled SCFAs. The systemic availability is the fraction of an administered dose of unchanged substrate that reaches the systemic circulation. In addition, the occurrence of interconversions was evaluated and the incorporation of the colonic-derived 13 C-SCFAs into glucose, free fatty acids and cholesterol was quantified. Stable isotope technology is a very sensitive analytical technique that allows the selective measurement in the plasma of those SCFAs that originate from the colon.
Methods

Ethical approval
The study procedure was approved by the Ethics Committee of Leuven University Hospital, Leuven, Belgium. Written, informed consent was obtained from all subjects and the study conformed to the Declaration of Helsinki. The study was registered at: ClinicalTrials.gov (NCT01757379).
Colonic delivery of SCFAs
Known amounts of the individual 13 C-labelled SCFAs ( 13 C-acetate, 13 C-propionate or 13 C-butyrate) were delivered into the colon of healthy subjects using colon delivery capsules (CDCs). Hard gelatine capsules (size 0) were filled with either ß200 mg of 13 C-labelled sodium acetate ([1- 13 C]acetate), 170 mg of 13 C-labelled sodium propionate ([1- 13 C]propionate) or 495 mg of 13 C-labelled sodium butyrate ([1- 13 C]butyrate) (Euriso-top, St Aubin, Cédex, France) together with 9.0% (w/w) citric acid (Sigma-Aldrich, Bornem, Belgium). The addition of citric acid was necessary to keep the pH of the capsule contents below pH 6.5 and to prevent dissolution of the coating from the inside-out as a result of water intrusion into the capsules. Before and after filling, the capsules were weighed to determine their exact content. The capsules were coated manually with a pH-dependent film made up of Eudragit S100 (Evonik, Darmstadt, Germany) with diethyl phthalate (Omega Pharma, Nazareth, Belgium) (25% w/w with respect to polymer) as plasticizer. Eudragit S100 only dissolves at a pH >7.0 (Chourasia et al. 2003) . The coating thickness was estimated from the increase in weight after coating and expressed as mg cm -² capsule surface. Coating thickness was varied between 13.5 and 23.3 mg cm -². Similar capsules containing 5.2 mg (in acetate capsules) or 4.0 mg (in propionate and butyrate capsules) of methylene blue were prepared to assess the pH resistance of the polymer coating. The release of methylene blue from the coated capsules was monitored during in vitro dissolution tests in sodium phosphate buffers (0.1 M) of pH 6.3, 6.8, 7.0 and 7.2 according to the USP XXV paddle method (150 rpm) at 37°C. The concentration of the marker was quantified colorimetrically at 664 nm. All measurements were performed in duplicate.
Study design
Twelve healthy subjects (seven female and five males, aged 26 ± 6 years, body mass index 22 ± 3 kg m -2 ) participated in a randomized, cross-over study. Exclusion criteria were previous abdominal surgery (except from appendectomy), history of chronic gastrointestinal conditions (e.g. inflammatory bowel diseases, irritable bowel syndrome and coeliac disease) or being on a low calorie or vegetarian diet. Female subjects were excluded if they were pregnant or lactating. All subjects were free of medication influencing the gut transit or intestinal microbiota for 14 days and of antibiotics for 1 month. Intake of preand probiotics was prohibited during the study period. Subjects were also excluded if they had donated blood during the last 3 months, suffered from low blood haemoglobin levels or had participated in experiments involving ionizing radiation during the last year. Each subject performed three test days (one type of SCFA per test day) with 1 week inbetween. During the 3 days prior to a test day, the subjects consumed a low-fibre diet and avoided alcohol intake. On the evening prior to the test day, a non-fermentable standard meal (lasagne) was offered to avoid changes in colonic fermentation during the different test days. On the morning of the test, the subjects received two coated capsules containing either 13 C-acetate, 13 C-propionate or 13 C-butyrate with a standard breakfast (pancake; 250 kcal) labelled with inulin-14 C-carboxylic acid (74 kBq; American Radiolabelled Chemicals, St Louis, MO, USA) as a marker for orocecal transit time (OCTT) (Verbeke et al. 2005 ) to quantify the clearance of each SCFA. Before breakfast and at regular time points during the day, breath, blood and urine samples were collected. Breath samples were collected every 20 min up to 10 h after breakfast. Blood samples were collected every 1 h during the first 4 h, every 20 min from 4 to 9 h, and every 40 min from 9 h to 12 h. A basal urine sample and 0-4 h, 4-8 h, 8-12 h and 12-24 h urine fractions were collected in recipients containing neomycin to prevent bacterial growth. After 4 and 8 h, the subjects received a standard non-fermentable meal (white bread with ham or cheese). Finally, all subjects delivered a faecal sample that, within 10 h after collection, was frozen at −80°C until analysis.
Analytical procedures
Analysis of breath samples. Measurements of 13 CO 2 , H 2 and 14 CO 2 in breath samples were performed as described previously (Verbeke et al. 2005) . The results for 13 CO 2 were expressed as cumulative percentages of administered dose (cumPDR) (Braden et al. 2007) . The time of release from the capsules (T 20% ) was defined as the time at which 20% of the cumPDR was recovered in the breath. The cumPDR values after 12 h were corrected for the 13 CO 2 that is produced via oxidation but is not excreted using a correction factor of 0.55 as suggested by Maurer et al. (2013) . The OCTT was defined as the time at which a significant increase in 14 C from background was seen in the breath (i.e. 2.5 times the SD of all previous points above the running average of all previous points) (Verbeke et al. 2005) .
Analysis of total SCFA concentrations in plasma and urine samples. Total SCFA concentrations in plasma were measured using gas chromatography (GC) after purification and concentration of the samples with hollow fibre supported liquid membrane extraction as described by Zhao et al. (2007) . To measure total SCFA concentrations in urine, samples (3.0 ml) were spiked with 150 μl of internal standard mix (83 mg l −1 2-ethyl-butyric acid and 200 mg l −1 3-methyl-valeric acid) and 500 μl of 1.0 M sodium hydroxide and concentrated to dryness. After the addition of 200 μl of 37.0% HCl to the residue, SCFAs were extracted in 1.0 ml of diethyl ether. The ether extracts were injected (0.5 μl) in pulsed splitless mode into the injector at 200°C. Chromatographic analysis was carried out on a fused-silica capillary column with Free Fatty Acid Phase (DB-FFAP 125-3237; J&W Scientific, Agilent Technologies, Santa Clara, California, USA) of 30 m × 0.53 mm inner diameter coated with 0.50 μm film thickness using an Agilent 6890 N GC system equipped with a flame ionization detector (Agilent Technologies). Column temperature was started at 100°C (3 min) and increased to 140°C (5 min) at a rate of 4°C min -1 followed by an increase to 235°C (5 min) at a rate of 40°C min -1 . Helium was used as carrier gas in a constant flow mode of 4.2 ml min −1 and the detector temperature was set at 240°C. The flow rates of the detector gases hydrogen, air and nitrogen as make-up gas were 30, 300 and Morrison et al. (2004) , whereas urine samples were only dried and extracted.
The extracted samples for analysis of 13 C-enrichment of SCFAs were injected (4 μl) in splitless mode at 240°C into a Delta-XP isotope ratio mass spectrometer (Thermo Fisher Scientific, Bremen, Germany) equipped with a Trace gas chromatograph and a combustion interface type 3 (GC-C-IRMS). An AT-Aquawax-DA column (30 m × 0.53 mm inner diameter and 1.00 μm film thickness; Grace, Lokeren, Belgium) was used. The initial oven temperature was 80°C (3 min) and ramped to 140°C at a rate of 4°C min -1 followed by an increase to 240°C (10 min) at a rate of 16°C min -1 . Helium was used as carrier gas in a constant flow mode of 2.5 ml min −1 . After elution from the GC column, the compounds were oxidized into CO 2 in the combustion reactor after which the enrichment was measured in the IRMS detector. To calculate the enrichment of the SCFAs from the measured 13 CO 2 enrichment, the number of labelled carbon atoms per molecule and the enrichment of the administered substrate ( 13 C-SCFAs) were taken into account. Data were processed using Isodat NT, version 2.0 (Finnigan TM ; Thermo Fisher Scientific).
For the analysis of the 2 H-enrichments of SCFAs, 1 μl of the extracted samples was injected at 240°C in splitless mode into the injector of a gas chromatograph equipped with a quadrupole system (Trace GC Ultra and DSQ II; Thermo Electron Corporation, Waltham, MA, USA) with an AT-Aquawax DA column (30 m × 0.25 mm inner diameter and 0.25 μm film thickness; Grace). The initial oven temperature was 40°C (3 min) and ramped to 140°C at a rate of 4°C min -1 followed by an increase to 240°C (6 min) at a rate of 16°C min -1 . Helium was used as carrier gas in a constant flow mode of 1 ml min −1 . The transfer line was maintained at 240°C. The mass spectrometer was operated in full scan monitoring mode (m/z 33-650) and the source temperature was set at 250°C. Xcalibur TM software (Thermo Fisher Scientific) was used for the automatization of the gas chromatographymass spectrometry (GC-MS) system and for data acquisition.
Analysis of 13 C-glucose. Total plasma glucose concentrations and 13 C-glucose enrichments were measured using GC-C-IRMS after derivatization of glucose to its aldonitrile penta acetate derivative according to Schierbeek et al. (2009) . The derivatized samples were injected (1 μl) in splitless mode into the GC-C-IRMS instrument equipped with an AT-5 ms capillary column (30 m × 0.32 mm inner diameter and 1.0 μm film thickness; Grace). The injector temperature was set at 250°C and the initial oven temperature amounted to 95°C (30 s) and was increased to 300°C (15 min) at 20°C min -1 . The helium carrier flowed at a constant rate of 1.5 ml min −1 . To calculate the enrichment of 13 C-glucose from the measured enrichment of 13 CO 2 , it was assumed that one propionate molecule was incorporated per glucose molecule.
Analysis of
13 C-free fatty acids. The concentrations and 13 C-enrichment in plasma of palmitic (C16:0), stearic (C18:0) and oleic (C18:1, n-9) acid were measured using GC-C-IRMS after prior conversion of the fatty acids into their corresponding methyl esters as described by Wang et al. (2012) . Samples were injected (1 μl) at 250°C in a splitless mode into an AT-aquawax-DA column (30 m × 0.53 mm inner diameter and 1.0 μm film thickness; Grace). The initial oven temperature was 50°C (2 min) and ramped to 200°C (10 min) at a rate of 10°C min -1 followed by an increase to 220°C (15 min) at a rate of 10°C min -1 . Helium was used as carrier gas in a constant flow mode of 2.5 ml min −1 . To calculate the enrichment of 13 C-fatty acids from the measured enrichment of 13 CO 2 , we assumed that one acetate molecule was incorporated per fatty acid molecule.
13 C-cholesterol. Plasma samples for 13 Cenrichment measurements of cholesterol were saponified and extracted in sequence with hexane and diethyl ether according to Paik et al. (2008) . The supernatant layer was silylated using N,O-Bis(trimethylsilyl)trifluoroacetamide. The 13 C-enrichment of cholesterol in plasma samples was measured using GC-C-IRMS analysis with an Rxi-5 ms capillary column (30 m × 0.25 mm inner diameter and 0.5 μm film thickness; Interscience, Breda, The Netherlands). Samples were injected (1 μl) in splitless mode at 250°C into the column. The initial oven temperature was 240°C (1 min) and was increased to 300°C (15 min) at 20°C min -1 . Helium gas was used as carrier gas and flowed at a constant rate of 2.5 ml min −1 . To calculate the enrichment of 13 C-cholesterol from the measured enrichment of 13 CO 2 , it was assumed that one acetate or propionate molecule was incorporated per cholesterol molecule. Total cholesterol concentrations were determined using standard laboratory techniques.
Analysis of butyrate-producing capacity in faecal samples.
Real-time PCR was used to quantify Clostridium cluster IV, Clostridium cluster XIV, butyryl-CoA:acetate-CoA transferase and butyrate kinase genes in faecal samples as described previously (Boets et al. 2015) .
Calculations
Systemic availabilities of colonic acetate, propionate and butyrate. The systemic availability of each SCFA was determined by measuring 13 C-acetate, 13 C-propionate and 13 C-butyrate plasma concentrations up to 12 h after colonic delivery of 13 C-acetate, 13 C-propionate and 13 C-butyrate, respectively, on three separate test days. At each time point, total (labelled + unlabelled) SCFA concentrations and 13 C-SCFA enrichments were measured. The plasma concentration of 13 C-SCFAs consists of the concentration of 13 C-SCFAs naturally present in the plasma and the concentration originating from the colon. The concentration of 13 C-SCFAs originating from the colon at each time point (n colon ) was calculated according to eqn (1) and allowed the construction of 13 C-SCFA concentration vs. time graphs:
where n tot is the total concentration of SCFAs (labelled + unlabelled); AP tot is the 13 C-enrichment of the SCFAs measured in plasma at time point t; AP plasma t0 is the 13 C-enrichment of the SCFAs measured in plasma at time 0; and AP colon is the 13 C-enrichment of the administered substrate.
To allow calculation of the clearance of the SCFAs, a primed constant infusion with 2 H-SCFAs was applied during each test day. The 2 H-enrichments of the SCFAs were multiplied by the SCFA plasma concentrations to calculate the 2 H-SCFA concentrations. Subsequently, the clearance (Cl; l h −1 ) was calculated from the 2 H-SCFA infusion rate (I 2H-SCFA ; μmol.h −1 ) and the steady state 2 H-SCFA plasma concentration (C ss ; μmol l −1 ) was obtained according to eqn (2):
13 C-SCFA concentration vs. time graphs were used to calculate the exposure to 13 C-SCFAs in plasma using the trapezoidal rule. Finally, knowing the administered amount of each 13 C-SCFA, the systemic availability of 13 C-acetate, 13 C-propionate and 13 C-butyrate was calculated according to eqn (3):
where SA is the systemic availability (%); AUC is the area under the curve of the 13 C-SCFA concentration vs. time graph (μmol h l −1 ); Cl is the clearance of the respective SCFA (l h −1 ); and D capsule is the administered dose of the respective SCFA (μmol).
Assimilation of SCFAs into biologically relevant molecules. The fraction of colonic-derived propionate used for glucose production was quantified from the cumulative amount of 13 C-glucose appearing in the plasma after colonic administration of 13 C-propionate according to eqn (4).
where F 13C-label recovered as glucose is the the fraction of administered 13 C recovered in glucose (%); AUC is the area under the curve of the 13 C-glucose vs. time graph (μmol h l −1 ); Cl glucose is the clearance (l h −1 ) of glucose that was calculated for each individual according to Jani et al. (2008) and amounted to 8.9 ± 1.2 l h −1 ; and D 13C-propionate is the dose of colonic administered 13 C-propionate (μmol).
Similarly, the fraction of 13 C-acetate incorporated into the most abundant fatty acids (palmitic, stearic and oleic acid) was calculated according to eqn (4) using the respective AUCs of the 13 C-fatty acids vs. time graphs, the clearance of palmitic, stearic and oleic acid, respectively, and the administered dose of 13 C-acetate. The clearance of the fatty acids was obtained from literature and amounted to 48, 30 and 45 l h −1 for palmitic, stearic and oleic acid, respectively.
Finally, the extent to which intestinal acetate and propionate were used for de novo synthesis of cholesterol was determined. The fractional incorporation of 13 C-acetate and 13 C-propionate into cholesterol was calculated according to eqn (4) using the AUC of the 13 C-cholesterol vs. time graph, the clearance of cholesterol and the administered dose of 13 C-acetate and 13 C-propionate, respectively. The clearance of cholesterol was calculated for each individual based on body weight and cholesterol levels as described by Turner et al. (2012) and amounted to 0.15 ± 0.04 l h −1 .
Statistical analysis
Statistical analyses were performed using SPSS, version 22.0 (IBM Corp, Armonk, NY, USA). All results are presented as the mean ± SD. Assumptions of normality were checked with a Shapiro-Wilk test. The OCTT and time of 13 CO 2 in breath samples were compared using a paired samples t test. Bivariate correlations were performed with Spearman's rho. Significance was accepted at the 5% level.
Results
Delivery of SCFAs into the colon of healthy subjects
In vitro dissolution tests indicated an appropriate release profile of the marker methylene blue from the CDCs J Physiol 595.2 (release after 45 min at pH 7.0) with a coating thickness of 18.8 mg cm -² capsule surface (Fig. 1A) . To evaluate the in vivo performance of the capsules, the time at which 13 CO 2 , resulting from oxidation of released 13 C-SCFAs, appearing in the breath was compared with the OCTT, which was estimated from an increase of 14 CO 2 in the breath (Verbeke et al. 2005) . A simultaneous increase in the breath of 13 CO 2 and 14 CO 2 indicates a correct release of the CDCs content in the proximal colon (Fig. 1B) . No significant differences were observed between the 13 CO 2 excretion time (383 ± 105 min) and the OCTT (399 ± 84 min) in any of the test days (P = 0.202) (Fig. 1C) .
Systemic availabilities of colonic acetate, propionate and butyrate 13 C-SCFA concentration vs. time graphs were constructed for the three test days of each subject and a representative example is shown Fig. 2A . By calculating the area under these 13 C-SCFA concentrations vs. time graphs, an exposure of 1.92 ± 1.13, 0.48 ± 0.26 and 0.21 ± 0.20 μmol h l −1 was obtained for 13 C-acetate, 13 C-propionate and 13 C-butyrate, respectively. Total body clearance of acetate, propionate and butyrate amounted to 938 ± 287, 647 ± 176 and 1237 ± 592 l h −1 , respectively. On average, the fraction of colonic-derived acetate, propionate and butyrate appearing in plasma amounted to 36 ± 21%, 9.2 ± 5.9% and 2.4 ± 1.9%, respectively (Fig. 2B ).
SCFAs are interconverted by gut microbiota
The individual 13 C-SCFAs were administered on separate days to allow evaluation of the extent of interconversion between the three SCFAs. After the administration of 13 C-acetate, the extent of its conversion into 13 C-propionate and 13 C-butyrate was determined by quantifying the appearance of 13 C-propionate and 13 C-butyrate in plasma. Interconversion was quantified in similar ways after the administration of 13 C-propionate and 13 C-butyrate. The incorporation of 13 C-acetate into butyrate (Fig. 3A) was quantitatively the most significant interconversion but all interconversions were detected. To confirm that conversion of acetate into butyrate was a result of bacterial metabolism and not human metabolism, uncoated 13 C-acetate capsules were administered. Because these released 13 C-acetate already in the proximal gastrointestinal tract, 13 C-acetate was absorbed before it had been in contact with bacteria and appeared in plasma already after 120 min. No 13 C-butyrate in plasma was observed, confirming that contact with bacteria is essential for the interconversion to occur (Fig. 3B and C) .
Quantification of the butyrate-producing capacity of the intestinal microbiota
To relate the interconversion of acetate into butyrate to the intestinal microbiota composition of the subjects, the butyrate-producing capacity in a faecal sample was quantified. RT-PCR was used to quantify genes coding for butyrate kinase and butyryl-CoA:acetate CoA-transferase, which are the dominant terminal enzymes in the production of butyrate (Louis & Flint, 2007; Vital et al. 2013) . In addition, the most abundant clusters of butyrate producing bacteria (i.e. Clostridium clusters IV and XIVa) were quantified (Fig. 4A) . However, the extent of acetate into butyrate conversion was not significantly related to any of these parameters of butyrate-producing capacity ( Fig. 4B-E) .
Utilization of colonic-derived propionate in gluconeogenesis
Plasma 13 C-glucose concentrations increased simultaneously with 13 C-propionate concentrations (Fig. 5A) . The cumulative amount of 13 C-glucose was 23 ± 20.5 μmol h l −1 . We calculated that 5.9 ± 4.7% of the colonic administered propionate was used for gluconeogenesis (Fig. 5B) .
Incorporation of acetate into fatty acids
The 13 C-enrichment and total concentrations of the most abundant plasma fatty acids, palmitic acid (C16:0), stearic acid (C18:0) and oleic acid (C18:1, n-9), were quantified after 13 C-acetate administration. Enrichment was mainly observed in palmitic acid and, to a lesser extent, in stearic and oleic acid (Fig. 5C ). Up to 12.0 ± 8.7%, 1.0 ± 0.9% and 1.0 ± 1.0% of administered acetate was assimilated into palmitic, stearic and oleic acid, respectively (Fig. 5D ). 
Figure 3. Cross-feeding of SCFAs
A, overview and quantitative indication of the interconversions between acetate, propionate and butyrate (n = 12). B, appearance of 13 C-acetate in plasma after administration of a coated and uncoated capsule filled with 13 C-acetate. Without coating, 13 C-acetate was released in the proximal intestine and appears at an earlier time in plasma compared to a coated capsule. C, appearance of 13 C-butyrate in plasma after administration of a coated and uncoated capsule filled with 13 C-acetate. 13 C-butyrate is only formed when 13 C-acetate is properly released in the colon.
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Incorporation of colonic-derived acetate and propionate into cholesterol
After administration of 13 C-acetate, 13 C-cholesterol readily appeared in plasma, whereas 13 C-cholesterol was hardly detectable after administration of 13 C-propionate (Fig. 5E ). Only 0.101 ± 0.076% and 0.007 ± 0.005% of administered 13 C-acetate and 13 C-propionate were assimilated into cholesterol, respectively (Fig. 5F ).
Conversion of SCFAs into carbon dioxide
The extent to which 13 C-substrates are converted to 13 CO 2 at the whole-body level is most often estimated from the excretion of 13 CO 2 in the breath. After 12 h, the cumulative percentage of 13 C-label recovered as 13 CO 2 in the breath after administration of 13 C-propionate amounted to 47 ± 13%, whereas 33 ± 10% of administered 13 C-acetate and 18 ± 3% of administered 13 C-butyrate was recovered (Fig. 6) . Application of the correction factor for the 13 CO 2 that is retained in the body indicated that up to 86 ± 24% of administered 13 C-propionate, 60 ± 18% of administered 13 C-acetate and 33 ± 6% of administered 13 C-butyrate was oxidized into 13 CO 2 within 12 h.
Urinary excretion
Subjects collected urine for 24 h in different fractions (0-4 h, 4-8 h, 8-12 h, 12-24 h) to allow quantification of the urinary excretion of 13 C-SCFAs. After 24 h, only up to 0.031 ± 0.020% of 13 C-acetate, 0.008 ± 0.002% of 13 C-propionate and 0.0006 ± 0.0003% of 13 C-butyrate were retrieved in urine.
Discussion
By applying a direct, stable isotope based approach, the present study provides quantitative information on the uptake and elimination of SCFAs in different body compartments and their assimilation into biologically relevant molecules in humans. This information may contribute to deciphering the mechanistic link between fibre consumption and its health benefits.
Colonic delivery of SCFAs
The targeting of orally administered compounds to the colon can be achieved using various strategies including the use of coatings with a pH-sensitive 11) . B-C, correlation between acetate into butyrate conversion and enzymes involved in butyrate synthesis (n = 11). D-E, correlation between acetate into butyrate conversion and the most abundant butyrate-producing bacteria (n = 11).
polymer, formulation of time-released systems, use of carriers that are specifically degraded by colonic bacteria, covalent linkage of the compound with a carrier, bioadhesive systems and osmotic controlled drug delivery systems (Charousia et al. 2003) . These formulations have been mainly developed to target drugs to the colon not only for the treatment of local diseases such as Crohn's disease or ulcerative colitis, but also because of the potential to deliver therapeutic peptides or proteins.
As a result of the absence of peptidases in the colon, the peptide drug might be absorbed unchanged after peroral administration. Targeted delivery of SCFAs to the colon has previously been achieved using carriers such as starch (Annison et al. 2003) or inulin (Chambers et al. 2015) . Upon arrival in the colon, the carriers are fermented by the resident bacteria and release the SCFAs that are attached to them. We preferred to use gelatine capsules with a pH-dependent coating as a convenient A, typical example that shows the appearance of 13 C-propionate followed by 13 C-glucose in plasma after colonic administration of 13 C-propionate. B, fraction of administered 13 C-propionate recovered in glucose (n = 12).
C, typical example that shows the appearance of 13 C-acetate followed by 13 C-palmitate, 13 C-stearate and 13 C-oleate in plasma after colonic administration of 13 C-acetate. D, fraction of administered 13 C-acetate recovered in palmitate (C16), stearate (C18) and oleate (C18:1) (n = 12). E, typical examples that show the appearance of 13 C-acetate and 13 C-propionate followed by 13 C-cholesterol in plasma after colonic administration of 13 C-acetate and 13 C-propionate. F, fraction of administered 13 C-acetate and 13 C-propionate recovered in cholesterol (n = 12). Results are expressed as the mean ± SD.
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vehicle to deliver well known amounts of SCFAs to the colon.
Systemic availability of SCFAs
Estimates of the extraction of the SCFAs during passage through the splanchnic bed have been reported and are based either on differences in SCFA concentrations in peripheral blood compared to their concentrations in portal blood obtained during abdominal surgery (Peters et al. 1992; Bloemen et al. 2009 ) or on isotope dilution experiments (Pouteau et al. 1996) . Estimates for splanchnic extraction of acetate vary from 40% to 75% (Pouteau et al. 1996; Vogt et al. 2004) , whereas an extraction value of 90% for propionate has been reported (Vogt et al. 2004) . Because butyrate is the preferred energy source for colonocytes, the majority of absorbed butyrate may already be consumed by the colonic mucosa. According to Cook and Sellin (1998) , 70-90% of butyrate is metabolized in the colonocytes (Cook & Sellin, 1998) . Bloemen et al. (2009) showed that the release of butyrate from the liver is not significantly different from zero, suggesting a splanchnic extraction of almost 100%. Of note, all studies mention a wide interindividual variation in SCFA levels, in both peripheral and portal blood (Peters et al. 1992; Bloemen et al. 2009 ).
We combined colonic administration of 13 C-labelled SCFAs with I.V. administration of 2 H-labelled SCFAs to determine the SCFA systemic availability, assuming a similar behaviour of both types of labelled SCFAs. Although simultaneous infusion of 13 C-acetate and 2 H-acetate in the gut of pigs resulted in higher 13 C-acetate than 2 H-acetate enrichment in plasma, suggesting in vivo isotope exchange of the deuterium hydrogen atoms in acetate and thus underestimation of the deuterium enrichment (Kien et al. 1996) , we did not find evidence for such isotope exchange in the present study. Indeed, the ion masses used to quantify acetate and 2 H 3 -acetate were m/z 60 and 63, respectively, with no quantifiable ions at mass m/z 61, nor 62. Similarly, we did not find evidence for isotope exchange of 2 H 7 -butyrate, which was quantified using a fragment ion with m/z of 63, rather than the parent ion. Therefore, even if isotope exchange occurred in the remaining part of the molecule, which we cannot exclude, this will not have affected our results. 2 H 5 -propionate was quantified using the parent ion at m/z 79. Although smaller peaks at m/z 78 and 77 were visible suggesting isotope exchange, the same ratios were observed in the infusion solution as in the plasma samples, indicating that the exchange probably occurred in the ion source of the mass spectrometer rather than in vivo.
The values for systemic availability of acetate (36%) and propionate (9%) obtained in the present study correspond to a splanchnic extraction of 64% and 91%, respectively, which is in good agreement with the reported values. Also in the present study, a large interindividual variation was observed. In addition, the direct stable isotope approach enabled the detection of 13 C-butyrate in the plasma after colonic administration of 13 C-butyrate and the quantification of its systemic availability (2%) or splanchnic extraction (98%).
Metabolism of SCFAs
Within 12 h after colonic administration, the vast majority of propionate (86%) was converted into CO 2 of which 47% was recovered in the breath. The remainder was retained in the body bicarbonate pool. Except from being a substrate for gluconeogenesis, no other pathways for the incorporation of propionate into other metabolites are known and the fate of propionate appears to be a rapid and almost complete conversion into CO 2 , which probably proceeds in the liver. These results do not allow differentiation between the fraction of propionate that is directly converted into CO 2 and that used for gluconeogenesis followed by oxidation of the resulting glucose into CO 2 . After administration of 13 C-acetate, recovery in the breath was lower compared to that of 13 C-propionate. This may be because the labelled C does not appear as 13 CO 2 but instead is exchanged in other metabolites. These are the most probable metabolites of the tricarboxylic acid (TCA) cycle (van Hall, 1999) because acetate enters the TCA cycle after conversion into acetyl-CoA. This exchange is only temporary because the resulting metabolites re-enter the oxidative pathways at a later time. This also explains the observation that breath 13 CO 2 recoveries after I.V. 13 C-acetate infusion increase with the duration of the infusion and only reach a plateau after 12 h of infusion (Mittendorfer et al. 1998) . Breath 13 CO 2 recoveries after colonic administration of 13 C-acetate have not been reported in the literature. Reported 13 CO 2 recoveries after I.V. 13 C-acetate administration vary from 40% to 81% (Wolfe & Jahoor, 1990; Pouteau et al. 1996; Mittendorfer et al. 1998) .
The low recovery of 13 CO 2 after administration of 13 C-butyrate (33%) is probably partly a result of the exchange of the label into TCA metabolites. After absorption in the colonocytes, butyrate is taken up in the mitochondria of the cells where it undergoes the β-oxidation pathway, which involves a series of five enzymes, to form acetyl-CoA that subsequently enters the TCA cycle (De Preter et al. 2012) . A few other studies that have compared the rate of colonic butyrate oxidation in patients with ulcerative colitis and healthy controls report on 13/14 CO 2 recoveries in the breath after colonic administration of 13 C-or 14 C-labelled butyrate. Six hours after rectal instillation of 14 C-butyrate enemas, 52.9% (range 44.4-61.5) of administered label was retrieved in the breath (Den Hond et al. 1998) . In another study, one quarter of rectally instilled 13 C-butyrate was recovered as 13 CO 2 after 4 h (Simpson et al. 2000) . After I.V. infusion of 13 C-butyrate in five healthy subjects, the 6 h cumulative excretion of 13 CO 2 amounted to 49.9 ± 2.2% (Den Hond et al. 1998) . For all 13 C-SCFAs, higher fractions of administered dose are excreted in the breath as 13 CO 2 than appear in the plasma, indicating that they are metabolized prior to arrival in the systemic circulation (i.e. presumably in the colonocytes and liver).
In the human kidney, monocarboxylate transporters (MCTs) are responsible for the reabsorption of SCFAs and ketone bodies (Halestrap & Meredith, 2004) . Although lactate is quantitatively the most important substrate for these transporters, they have also been shown to reabsorb SCFAs. As a consequence, urinary excretion of SCFAs is low. After continuous infusion of sodium butyrate for 10 days in patients with acute leukaemia, only 0.21 ± 0.04‰ of the administered dose was retrieved in urine (Miller et al. 1987) . In healthy subjects, urinary levels of SCFAs have been reported in the range 0.8-130 μM for acetate and below 3 μM for propionate and butyrate (Perry et al. 1970 ).
In vivo cross-feeding
Cross-feeding involves the supply of breakdown products of carbohydrates after partial hydrolysis by primary degraders as secondary substrates to other bacteria (De Vuyst & Leroy, 2011) . In particular, acetate is known to function as an intermediate in cross-feeding interactions between colon bacteria, and plays a key role in colonic butyrate production (Morrison et al. 2006; Riviere et al. 2015) . Morrison et al. (2006) incubated human faecal slurries in vitro with 2 H-labelled SCFAs and quantified the interconversion between the SCFAs. After 6 h, 0.28 mol mol -1 labelled acetate was incorporated into butyrate. In the present study, conversion of 13 C-acetate into 13 C-butyrate was estimated to be ß24%. Although the contact time of 13 C-acetate with the intestinal microbiota was shorter in vivo than in vitro because 13 C-acetate was rapidly absorbed into the plasma after release from the CDCs, the value is only slightly lower than the data of Morrison et al. (2006) , suggesting that this interconversion proceeds quite rapidly. Although no evidence for incorporation of 2 H-acetate into propionate or 2 H-propionate into butyrate was found in the in vitro study, all possible interconversions could be detected, although this was to a lower extent than the acetate into butyrate interconversion. This discrepancy is probably a result of the different analytical techniques used in both studies. Morrison et al. (2006) applied GC-MS analysis, which allowed differentiation between different isotopomers of the SCFAs, although this is a less sensitive technique than the isotope ratio mass spectrometry applied in the present study. In a recent study in mice, enrichments of cecal SCFAs were quantified after 6 h of cecal infusion of 13 C-labelled SCFA. A high conversion was observed from acetate into butyrate, whereas there was a low conversion from butyrate into acetate and between butyrate and propionate, and very little interconversion between acetate and propionate (den Besten et al. 2013a ).
Propionate as a substrate for gluconeogenesis
Studies in lactating cows report that up to 61% of glucose in blood is derived from gluconeogenesis with propionate as the substrate (Wiltrout & Satter, 1972) . In sheep, corresponding values between 42% and 59% have been reported (Leng et al. 1967) . On the other hand, up to 32% of colonic-derived propionate is incorporated into glucose in sheep and up to 62% in mice (Leng et al. 1967; den Besten et al. 2013a ). Compared to those values, the extent of incorporation of colonic-derived propionate into glucose (5.9%) is limited in humans, as shown by the results of the present study. Indeed, propionate is the major substrate for gluconeogenesis in ruminants (Bergman, 1990) whereas, in humans, lactate and pyruvate are the major gluconeogenic substrates with minor contributions of alanine and glycerol (Garber et al. 1974) . Several methods based on stable isotope technology have quantified in vivo the contribution of gluconeogenesis to the glucose production in humans (Previs & Brunengraber, 1998) . However, the contributions of all gluconeogenic substrates are included in these estimates and no human data on the contribution of propionate to gluconeogenesis are available.
More recently, in rats, it has been shown that propionate is incorporated into glucose at the level of the intestine (De Vadder et al. 2014) . The resulting glucose is sensed in the walls of the portal vein and induces a nervous signal to the brain that influences food intake and glucose homeostasis. These results may provide a mechanistic role J Physiol 595.2 for propionate in the beneficial effects of dietary fibre. Unfortunately, because of an inability to obtain portal blood from healthy subjects, our results do not allow determination of whether the observed incorporation of 13 C-propionate into glucose occurs in the intestine or in the liver.
Incorporation of acetate into fatty acids
Indirect methods to estimate de novo lipogenesis such as indirect whole-body calorimetry, as well as direct methods such as 2 H 2 O infusion and mass isotopomer distribution analysis, confirmed that de novo lipogenesis (DNL) is a quantitatively minor pathway under normal conditions of typical high-fat diets (Bjorntorp and Sjostrom, 1978; Hellerstein et al. 1991; Hellerstein et al. 1996) . Absolute DNL was estimated at less than 1 g being synthesized per day, which is low compared to a dietary fat intake of typically 100 g day -1 (Hellerstein et al. 1996) . Studies using mass isotopomer distribution analysis I.V. infuse 13 C-acetate to enrich the acetyl-CoA-precursor pool and express the fractional hepatic DNL as fraction of newly synthesized lipid compared to the lipid already present and not as fraction of administered acetate incorporated in the lipid. As a consequence, it is not possible to compare the results obtained in the present study with the results reported in literature. Almost 15% of colonic-administered acetate was incorporated into fatty acids in the present study. However, this only corresponds to an absolute amount of 0.229 ± 0.175 g of newly synthesized fatty acids, which is still far below the 1 g threshold. It needs to be taken into account that only 5 mmol of 13 C-labelled acetate was administered in the colon delivery capsules, whereas the amount of acetate produced in the colon on a western diet (20 g of dietary fibre) has been estimated at ß150 mmol per day (Wolever et al. 1995) .
Incorporation of acetate and propionate into cholesterol
It has been calculated that the rate of de novo synthesis of cholesterol amounts to 10 ± 6 mg kg −1 day −1 in healthy adults (Renfurm et al. 2004) . Because the biosynthesis of cholesterol starts from the two-carbon acetate group of acetyl-CoA, it has been suggested that dietary fibres that are fermented into a high proportion of acetate might increase serum cholesterol levels. However, unlike propionate and butyrate, the majority of plasma acetate originates from endogenous metabolism and the contribution of colonic-derived acetate to cholesterol synthesis may be less important. Indeed, the present study showed that less than 0.1% of colonic-administered acetate was incorporated into cholesterol. This value is of the same order of magnitude as the value of 0.7% reported by Hellman et al. (1954) after oral administration of 14 C-acetate. In mice, the fractional synthesis of cholesterol from acetate was 0.7 ± 0.1% (den Besten et al. 2013a ). Propionate did not contribute to cholesterol synthesis, neither in the present study, nor in the study in mice by den Besten et al. (2013a) .
Limitations of the present study
For calculation of the systemic availability, it was assumed that the absorption of the 13 C-SCFAs from the colonic lumen was quantitative. The major part of SCFAs is transported in dissociated form across the apical membrane of the colonocytes by MCT-1, the electrogenic sodium-dependent MCT-1 or an SCFA-HCO 3 − exchanger of unknown identity (den Besten et al. 2013) . It is generally assumed that the colon has a large capacity to absorb SCFAs, with estimates of 6.1-12.6 μmol cm -² h -1 (He et al. 2006) . Because the human colon has a mucosal surface area of ß20 000 cm² (Helander & Fandriks, 2014) , up to 120-250 mmol of SCFAs could be absorbed every 1 h. To confirm a quantitative SCFA absorption, a complete stool collection for 3-5 days after each test day would have been required for quantifying residual 13 C-SCFAs. This would have placed an additional burden on the protocol, which was already onerous for the participants, and therefore this was not performed. Only one stool sample was collected for the analysis of the microbial butyrate-producing capacity.
In the present study, the metabolic fate of the SCFAs was evaluated in standardized feeding conditions (i.e. after administration of a non-fermentable standard breakfast and lunch). Whether the oxidation and/or incorporation of SCFAs in biomolecules differs in fasting conditions remains to be investigated.
Conclusions
The set-up and methodology used in the present study allowed quantification of the percentages of acetate, propionate and butyrate originating from the colon that reached the systemic circulation. In addition, the metabolism and assimilation of acetate, propionate and butyrate into biologically relevant molecules were measured.
In the future, these results will allow the evaluation and quantification of SCFA production from varying 13 C-labelled fibres in the human colon by measurement of 13 C-labelled SCFA concentrations in the blood and multiplication of the amounts of SCFAs that reached the plasma with the systemic availability index calculated in the present study. In addition, the availability of plasma clearance values for each SCFA will allow calculation of fluxes under different conditions when combined with plasma SCFA measurements.
